EP1144667A2 - Vecteurs d'expression retroviraux a base de sequences herv-ltr (=sequences nucleotidiques d'adn a longue repetition terminale) - Google Patents

Vecteurs d'expression retroviraux a base de sequences herv-ltr (=sequences nucleotidiques d'adn a longue repetition terminale)

Info

Publication number
EP1144667A2
EP1144667A2 EP00918779A EP00918779A EP1144667A2 EP 1144667 A2 EP1144667 A2 EP 1144667A2 EP 00918779 A EP00918779 A EP 00918779A EP 00918779 A EP00918779 A EP 00918779A EP 1144667 A2 EP1144667 A2 EP 1144667A2
Authority
EP
European Patent Office
Prior art keywords
herv
retroviral
cell
sequences
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00918779A
Other languages
German (de)
English (en)
Inventor
Christine LEIB-MÖSCH
Ulrike SCHÖN
Corinna Baust
Robert Michael Saller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gsf-Forschungszentrum fur Umwelt und Gesundheit G
Original Assignee
Austrian Nordic Biotherapeutics AG
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Austrian Nordic Biotherapeutics AG, Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH filed Critical Austrian Nordic Biotherapeutics AG
Publication of EP1144667A2 publication Critical patent/EP1144667A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • the present invention relates to retroviral expression vectors with cell-specifically regulable promoters.
  • the vectors can be used, for example, for cell-specific expression of therapeutically valuable genes in the context of gene therapy.
  • Retroviruses are RNA viruses in which the viral genes are encoded by a single-stranded RNA molecule. After the viruses have entered the cell, the viral RNA is converted into a double-stranded DNA molecule by reverse transcription. The DNA penetrates into the nucleus and integrates into the cellular chromosome. The integrated viral DNA form, the so-called provirus, forms the template for the expression of the viral genes.
  • the integration of the viral genome into the cellular chromosome is a mandatory part of viral replication and is mediated by virally encoded enzymes. It appears that, with a few exceptions, the presence of the retroviral genome in the cell, the expression of its genes, and the formation of virus particles do not or hardly affect the viability of the infected cell.
  • Retroviraier gene transfer is used to introduce functional genes, especially therapeutically valuable genes, into the cells without affecting the proliferation ability of the host cell. Because of their replication mode, retroviruses are suitable for such a gene transfer. In the simplest embodiment, at least some of the viral genes are replaced by a gene of interest and, with the aid of the efficient viral infection process, this gene of interest is transferred to the target cell.
  • Retroviral vectors are suitable for gene therapy because the infection by retroviruses is highly efficient and the retroviral vectors can be modified in such a way that they take up heterologous DNA and can integrate it stably into the host cell genome.
  • retroviral vectors have been developed in recent years, and only for example is the review article by Günzburg et al. (1996) and Robbins et al. (1998).
  • a possible preferred embodiment for retroviral vectors are so-called ProCon vectors, which were first described in WO 96/07748. For the purposes of disclosure, reference is made in full to this publication.
  • ProCon vectors carry heterologous promoter and optionally other regulatory elements in the 3'LTR, which, after infection, are duplicated and translocated to the 5'LTR in the target cell and which are able to regulate the expression of marker genes or therapeutic genes. These heterologous genes are not directly linked to the promoter, but are inserted into the interior of the vector.
  • ProCon vectors comprise a 5'LTR section of the structure U3, R, U5 and at least one coding and / or non-coding sequence and a 3'LTR area which comprises a completely or partially deleted U3 section, the deleted one U3 section was replaced by a polylinker sequence, followed by the R and U5 section.
  • helper cell line which produces large amounts of the viral proteins which are no longer synthesized by the expression vector itself.
  • helper cell line is no longer able to produce a replication-competent virus.
  • This cell line is also referred to as a packaging cell line and comprises a cell line transfected with at least one second plasmid which carries those genes which enable packaging of the modified retroviral vector.
  • W092 / 10564 we refer here e.g. to W092 / 10564, to which reference is made here in full.
  • the DNA coding for the modified retrovirus is transfected into the packaging cell line.
  • the modified retroviral genome including the inserted therapeutic genes or marker genes is transcribed and packaged into the retroviral particles (recombinant viral particles).
  • This recombinant virus is then used to infect the target cells; the genome of the modified retrovirus, ie the expression vector, is integrated into the genome of the target cells, together with the marker genes or the therapeutic genes.
  • a cell infected with the recombinant viral particles generated in this way can no longer produce a new vector virus since there are no further viral proteins in these cells.
  • the in the hosts « cell-integrated DNA of the expression vector with the therapeutically valuable genes or the marker genes is integrated in the cellular DNA and can now be expressed in the cell.
  • cell-specific regulatory sequences are used in the LTR sequence of the expression vector.
  • These cell-specific regulatory sequences include, for example, cell-specifically regulatable promoter sections, cell-specific enhancer sequences and transcription factor binding sites.
  • the promoters are in the U3 section of the LTR.
  • Cellular promoter sequences or promoter sequences of exogenous retroviruses are currently used in retroviral vectors.
  • Cellular promoters are often dependent on additional signal structures that can be located at a great distance upstream or downstream of the promoter. It has therefore repeatedly proven difficult to isolate strong, tissue-specific cellular promoter sequences and to clone them in retroviral vectors. Promoters of exogenous retroviruses have the advantage that they contain all the necessary regulatory elements in a small space in the retroviral LTR and are therefore largely transcribed independently of the neighboring DNA sequences of the integration site. A serious disadvantage, however, is that, although they are very strong, they are not tissue-specific and are usually expressed equally strongly in all cell types.
  • a cell-specifically regulatable promoter section from a human endogenous retroviral DNA nucleotide sequence is used in retroviral expression vectors.
  • HERV human endogenous retroviral DNA nucleotide sequence
  • Endogenous retroviruses can be found in the genome of all cells in an organism. They are transmitted vertically via germline cells and can be reactivated by environmental influences.
  • the human genome consists of approximately 2% endogenous retroviruses and retroviral sequences, with solitary HERV-LTRs with 20,000-40,000 copies per genome being represented (Tab. 1) (Leib-Mösch et al., 1993; Wilkinson et al., 1994 , Patience et al., 1997).
  • Retroviral vectors that are constructed from such sequences have the advantage over vectors from animal viruses that no new viral sequences have to be introduced into the genome. Even by recombination with HERV sequences already present in the genome, no new types of retroviruses can arise, e.g. the case would be if retroviruses of other species are used as vectors. For this reason, the use of these sequences to construct retroviral vectors can minimize the security risk. Furthermore, homologous regions contained in the genome could be used for tissue-specific integration of the retroviral vectors into specific locations of a chromosome.
  • HERV elements have taken on a number of cellular functions during evolution.
  • promoter and enhancer elements of HERV LTRs are used to control the transcription of cellular genes (Kato et al., Feuchter-Murthy et al., 1993; Di Christofano et al., 1995).
  • An example of the use of LTR regulatory elements for tissue-specific expression of a cellular gene is the human amylase gene. This gene is controlled by the LTR of a HERV-E element and is therefore only specifically expressed in the salivary glands (Ting et al., 1992).
  • retroviral promoters have persisted in the primate genome for millions of years, they have adapted in the course of evolution so that, like cellular promoters, they are cell type-specific, thus combining the advantages of cellular and retroviral promoters.
  • HERV-LTRs also contain a large number of different binding sites for transcription factors (Seifarth et al., 1998), which are responsible for the tissue specificity of the expression.
  • HERV sequences and especially promoters of HERVs have never been considered as possible candidates for the development of retroviral expression vectors.
  • they have so far only been regarded as disruptive factors in connection with gene therapy (Patience et al., 1997). It was feared that they could interfere with the therapeutic vector in the target cell by recombinations due to sequence homologies. So far, these fears have not been confirmed experimentally, but with the development of very efficient human packaging cell lines, the problem of co-packaging and the unwanted transmission of potentially infectious HERV sequences has arisen.
  • HERV genes have a sequence homology to MLV genes of 50-65%, the areas essential for packaging and infection, in particular the packaging signal located between the 5 'LTR and the gag region and the LTR itself, do not have any recognizable sequence homology to the corresponding MLV sequences.
  • Efficient HERV packaging systems are also currently unimaginable, since no cell lines are known to date that produce HERV particles in sufficient quantities.
  • the present invention thus solves the problem of retroviral expression vectors which control cell and tissue-specific expression of foreign genes (gene of interest) by providing expression vectors which, in a functional arrangement, contain at least the following elements:
  • DNA sequences for cell-specific expression are characterized in that they comprise a cell-specifically regulatable promoter region which originate from a human endogenous retroviral virus, in particular the LTR sequence of this virus;
  • the promoter region from a HERV sequence can encompass the entire LTR region of the HERV. In further embodiments of the invention, however, the promoter region only comprises the U3 region or the R-U3 region of the HERV-LTR. In a further preferred embodiment of the invention, in addition to these regions, the untranslated region between the 5 'LTR and the gag genes is also included in the promoter section. According to the invention it was found that sequences are also located in this area which control cell-specific expression of proteins or peptides, ie are at least partly responsible for this cell-specific expression.
  • the promoters are sections of the DNA which are necessary for the start of the transcription of the assigned structural genes.
  • the promoter contains the starting point of the transcription, the recognition and binding site for the RNA polymerase.
  • the promoter can also comprise further sequences to which regulatory proteins can bind and thereby specifically regulate the initiation of transcription. Examples of such proteins are transcription factors and repressors. Examples of these regulatory elements of transcription activity are the CAAT box, the GC box and the TATA box.
  • the promoters are recognized by a type II polymerase.
  • the promoter sections for cell-specific expression of foreign proteins from HERVs can optionally be combined with further sequences which originate from exogenous retroviruses and which promote cell-specific expression.
  • a combination with regulatory sequences from cellular genes is also conceivable to support cell-specific expression.
  • the retroviral expression vector according to the invention further contains at least DNA sequences for packaging the vector by a packaging helper cell line.
  • the packaging DNA sequences are located between the 5 'LTR and the gag gene.
  • packaging signals are present in all retroviral vectors and are therefore known to the person skilled in the art. Examples of packaging sequences are listed in Mann et al., 1985, and Rein, 1994, and the literature cited therein. Full reference is made to this literature.
  • the retroviral expression vector of the present invention contains one or more transcription units that code for an amino acid sequence.
  • the amino acid sequence stands for a protein or peptide. Any sequence that encodes any protein or peptide of interest can be inserted into the expression vector. Such proteins or peptides can be encoded, for example, by marker genes, therapeutically valuable genes, genes with an antiviral effect, antitumor genes and / or cytokine genes. This list could be supplemented as desired.
  • the inserted into the retroviral expression vector The genes are known to the person skilled in the art. The type of genes used depends on the intended use of the vector according to the invention.
  • the vectors according to the invention can be used, for example, in gene therapy to transfer heterologous DNA into target cells in order to make diseases accessible to a specific therapy.
  • the vector DNA is introduced into the selected target cells so that the heterologous DNA is expressed in the target cell and the product encoded by the DNA is produced.
  • These include in particular those genes for the expression of proteins which are not produced in the target cell or are no longer produced or are produced in insufficient quantities, so that a disease state arises.
  • the invention includes not only those proteins or peptides that occur naturally, but also those that have been modified in such a way that a desired effect is achieved, for example a higher activity of an enzyme, the blocking of the binding site of viruses, destruction of tumor cells through suicide genes etc.
  • the DNA nucleotide sequences coding for a protein or a peptide are generally heterologous DNA which codes for RNA and proteins which are normally not produced in vivo by the cell in which the proteins or peptides are expressed. It can also be called foreign DNA. Any proteins, for example enzymes, hormones and antibodies, are included.
  • the retroviral expression vectors provided according to the invention are therefore designed such that they can express proteins of interest in human cells.
  • the promoter regions used according to the invention are selected from HERV sequences which come from the known HERV families. Examples include HERV-K, HERV-H, HERV-E, HERV-L, HERV-T, HERV-R, HERV-I, HERV-P, ERV9, HERV-W.
  • HERV families which are not yet known can of course also be screened in order to find as yet unknown promoter sequences which control cell-specific expression.
  • LTR sequences from HERVs which are preferred according to the invention and which can be used for the tissue-specific expression of proteins and peptides of interest are set out in the appendix disclosed. They can be used in retroviral expression vectors in order to achieve the object of the invention. Of course, only parts of these LTRs can be selected by methods known per se in order to keep the sequences used in the vector as small as possible. The appropriate fragments can be selected using various deletion mutants. Further modifications of these LTR sequences are also possible, for example point mutations, insertions, additions, exchange of several nucleotides etc. in order to increase the efficiency of the tissue-specific expression and to adapt it to the desired function.
  • the ProCon vectors described at the outset are used.
  • Such ProCon vectors include a 5 'LTR portion of structure U3-R-U5, one or more sequences encoding a protein or peptide, and optionally non-coding sequences, and a 3' LTR portion comprising a partial or Completely deleted U3 section, the deleted U3 section comprising at least the HERV-LTR sequences used according to the invention, followed by the R-U5 section. Further details are described, for example, in WO96 / 07748 and WO96 / 28564. Full reference is made here to these writings.
  • the retroviral expression vectors according to the invention are packaging-deficient, ie they are unable to produce virus particles without the aid of a packaging helper cell line.
  • the invention therefore also comprises a retroviral vector system which contains a retroviral expression vector as described in the present invention and a packaging cell line with at least one retroviral or recombinant retroviral construct which codes for the packaging proteins of the retroviral expression vector.
  • packaging cell lines are known and described per se. For example, reference is made here to the murine packaging cell line PA317 (Salier et al., 1998). In the following, the invention is first described in general and then using exemplary embodiments.
  • the suitability of human endogenous retroviruses for the development of tissue-specific vectors for gene therapy was investigated.
  • tissue specificity of the HERV pol transcription in various cell lines such as T cells, keratinocytes and breast cancer cells was first checked in a "reverse dot blof" procedure.
  • the expression patterns of the various HERV families were found to be entirely dependent on the cell type
  • primers were developed with which the U3 / R regions from mRNA preparations can be specifically amplified. The isolated LTR sequences and individual representatives of already known LTRs were incorporated into expression vectors.
  • the activity of the LTR promoters was tested after transient transfection of the reporter plasmids via luciferase activity or via eGFP fluorescence in different cell lines, and it was found that the promoter activities of the individual HERV LTRs vary significantly depending on the cell line tested -H LTR, which from A Strocytes and liver cells had been isolated and had proven to be particularly active in lung fibroblast cells (LC5) in several experiments, were inserted into two retroviral promoter conversion vectors (pLESN and PLX), tested in packaging cell lines, the packaging efficiency examined and checked to see if Infection of the target cells a promoter conversion has taken place. FACS analyzes were carried out to demonstrate the transcription activity in the target cells.
  • HERV promoter sequences U3 / R region
  • tissue specificity and promoter activity of these sequences was then tested in a transient transfection assay in various human cell lines.
  • suitable sequences were selected, cloned into a promoter conversion vector (ProCon vector) and their suitability for the construction of tissue-specific vectors for gene therapy was checked.
  • the retroviral expression vectors according to the invention are produced by recombinant techniques known per se. Such techniques are described, for example, in Sambrook et al., 1989, and Perbai, 1984. tion of the ProCon vectors, reference is made to WO 96/07748 already mentioned at the outset and the literature associated therewith.
  • tissue-specific expression of a retrovirus is primarily determined by its U3 region. All regulatory sequences such as promoter, enhancer and the binding sites for various cellular transcription factors are located in this area. For this reason, primers were developed with which these HERV sequences could be isolated from mRNA of different cell lines by RT-PCR (Tab. 2; Fig.1). About 30 different HERV-LTRs were cloned in this way. Part of these sequences were tested in a reporter plasmid for promoter activity and tissue specificity.
  • a polydT primer was combined for the PCR with a primer that is complementary to the polypurine tract (PPT) of the retroviral RNA (Fig. 1).
  • PPT polypurine tract
  • the PPT tract is a conserved region in the untranslated area between the env gene and the U3 Region of the 3'-LTR.
  • the PPT region is used as the primer binding site for the synthesis of the plus strand during the reverse transcription of the retrovirus (Sorge and Hughes, 1982).
  • epithelial cells HeLa, HaCaT
  • fibroblast cells LC5
  • T cells H9, HUT78
  • lymphoblasts CML
  • gnome cells 85HG66, U373
  • pancreatic cells MiaPaCa2, Pand
  • liver cells Chang Liver
  • breast cancer cell lines T47-D, MCF7
  • cDNA gene banks (Clontech) from various human tissues (brain, heart, liver, kidney, lung, pancreas, placenta, Skeiett muscle) were used for the RT-PCR.
  • the fragments obtained were then cloned, sequenced and analyzed using database comparisons. From the PCR fragments obtained with the PPT and polydT primers, two LTRs could be assigned to the HERV-H and HERV-K families via homology comparisons. By using polydT primers in these PCR approaches, numerous sequences were amplified that did not contain any homologies to known retroviral LTRs and, furthermore, did not contain any promoter structural elements. For this reason, further sequences from conserved areas of the U3 region and from the R region of HERV-K and HERV-H families were selected for primer synthesis (Mold et al., 1997), (Fig. 1, Tab. 1).
  • HERV-LTRs HERV-K-pl167, HERV-H-H6, HERV-E, HERV-L
  • the hybridizing fragments were then cloned into a vector (pZE-RO, Invitrogen) and sequenced.
  • HERV-LTRs which are listed in Table 3, were isolated using this method.
  • the HERV-K-LTRs which were isolated from human brain and heart tissue as well as from T47-D cells, show very high sequence homologies to the 3 ' LTR of HERV-K10.
  • the HERV-H LTRs show much higher sequence variabilities.
  • HERV-H31, HERVHS, HERV-HCM1, HERV-HCM4, HERV-HMP23 are homologous to that of Mager et al. isolated HERV-H-H6 LTR, the other HERV-H sequences show homologies to that of Anderssen et al. (1997) isolated HERV-H LTRs from monkeys, marmosets and humans.
  • the HERV-W LTRs isolated from T47-D cells are related to the LTR of clone CL6 (Komurian-Pradel, 1999).
  • HERV-LTRs To analyze the promoter activity and the tissue specificity of the isolated HERV-LTRs, these were first cloned into a luciferase reporter plasmid (pBL, Butz, K., DKFZ, Heidelberg). This vector contains the Photinus pyralis luciferase gene fused to the SV40 polyA signal from pBLCAT2 (Hoppe-Seyler et al., 1991).
  • the individual vector constructs were transiently transfected into different cell lines. After 48 hours, the luciferase activity from the cell lysate was measured with the luciferase assay kit from Promega and, after comparing the ⁇ -galactosidase activity or the Renilla luciferase activity, determined as relative luciferase activity.
  • the promoter activities of the LTRs were in epithelial cells (HeLa, HaCaT), fibroblast cells (LC5), T cells (H9, HUT78), glioma cells (85HG66, U373), liver cells (Chang Liver), pancreatic cells (MiaPaCa2, Pand) and breast cancer cell lines (T47 -D, MCF7).
  • the results are shown in Figures 2a - 2f.
  • the HERV-H-H6 LTR therefore has the strongest promoter of all endogenous LTRs examined.
  • the HERV-K LTR from placenta is particularly active in HeLa cells. This LTR is only very weakly active in all other cell lines.
  • HERV-K-T47-D also showed a strong activity in HeLa cells, this LTR was also active in HaCat cells and pancreatic cells.
  • the HERV-L LTR has strong promoter activity in liver cells and is weakly active in T cells and pancreatic cells.
  • the HERV-T-S71A and HERV-E LTRs were not active in any celline tested. So far, no activity of a HERV-LTR has been observed in CML cells.
  • HERV-H LTRs (HERV-H1, HERV-H8, HERV-H13, HERV-H19, HERV-H-H6, Table 3) were almost all active in 85HG66 lines, with HERV-H 1 and HERV-H8 showed the highest activity in this cell line (without figure).
  • HERV-H19 was very active in HeLa cells.
  • the HERV-HCM1 LTR showed the highest promoter activity in all cell lines and was particularly active in lung fibroblasts (LC5) (Fig. 3).
  • Hybrid HERV / MLV vectors were constructed using two MLV-based vectors pLESN-MMTV (Fig. 7) and pLX-MMTV (Fig. 8). These vectors contain the EGFP gene as reporter gene, which is expressed from the 5 'LTR (different, depending on whether before or after the promoter conversion), and a neomycin gene, which is expressed from an SV40 promoter.
  • the vector pLX-MMTV contains a prokaryotic replication original, which allows the provirus to be recloned for further molecular characterization.
  • the MMTV-LTR was replaced by the HERV-HCM1 LTR (Fig. 7).
  • the LTR was first amplified by means of PCR from the vector pBL-HERV-H with specific primers which contained additional sequences for the restriction enzymes Mlul and Sacll. These fragments were then inserted into the 3 ' U3 deleted vectors.
  • the reporter gene EGFP is first expressed from the MLV promoter after transfection into the packaging cell line. (Fig. 9a) After infection of the target cells and successful promoter conversion by reverse transcription in the target lines, the reporter gene is under the transcription control of the HERV LTR.
  • the HERV-Hybrid vector constructs pLESN-HERV-H (Fig. 7) and pLX-HERV-H (Fig.8), as well as the origin vectors pLESN-MMTV and pLX-MMTV were transfected into the amphotrophic packaging cell line PA317.
  • the resulting retroviral vector particles were then used to infect the CrfK and LC5 cell lines.
  • the infected cell lines were cloned and the selected cell clones were examined to determine whether they contained the vector constructs and whether the promoter conversion had taken place.
  • chromosomal DNA was prepared from infected and uninfected cells and analyzed by PCR.
  • the primers were selected from the MLV U3 (P5) and R (P2) region and from the HERV-H region (P1) and used in combination with a primer from the EGFP region for a PCR (Fig. 9a).
  • the PCR products were hybridized with HERV-H specific probes (Fig. 9b).
  • the promoter activity of the HERV LTR in the retroviral vectors was determined after integration into the DNA of the target cells by means of FACS analyzes by measuring the EGFP fluorescence (FIG. 10).
  • the activity of the starting vector pLX-MMTV was compared with the HERV vector pLX-HERV-H (H6) before and after induction with dexamethasone.
  • the vector with the MMTV LTR can be activated by dexamethasone.
  • the HERV LTR vector is not activated by dexamethasone, but it is approximately 10 times more active than the dexamethasone-stimulated MMTV hybrid vector.
  • the presence of R sequences leads to a significant increase in the pro- motor activity (Fig.4a).
  • group 2 LTRs L20 / L49
  • the activity of the HERV promoter is reduced by the R region (FIG. 4b).
  • the HERV-K-T47D promoter (Fig. 5) and the L48 promoter are not significantly influenced by the corresponding R sequences.
  • sequence regions that are located downstream of the U3-R region and include the U5 region, as well as the 3 ′ untranslated region and the beginning of the gag gene have a clear activating effect (Fig. 5).
  • Group 1 LTRs in the R region have a binding site for the transcription factor SP1 that is missing in the Group 2 R region LTR (FIG. 6).
  • the group 2 R region contains a potential binding part for the factor TFS3, which acts as a transcription repressor. This shows that the activity of HERV promoters can be modified by incorporating additional regulatory elements such as transcription factor binding sites, enhancer sequences or negatively regulating elements.
  • Human proviral mRNAs down-regulated in choriocarcinoma encodes zinc finger protein related to Krüppel. Mol. Cell.
  • Patience, C Takeuchi, Y., Cosset, F.-L, Weiss, R.A. (1998). Packaging of endogenous retroviral sequences in retroviral vectors produced by murine and human packaging cells. J. Virol. 72, 2671-2676.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des vecteurs d'expression rétroviraux avec de promoteurs régulables de manière spécifique des cellules. Ces vecteurs s'utilisent par exemple pour assurer l'expression spécifique des cellules de gènes utiles sur le plan thérapeutique dans le cadre d'une thérapie génique. L'invention concerne des vecteurs d'expression rétroviraux contenant au moins les éléments suivants en configuration fonctionnelle: a) des séquences d'ADN pour encapsider l'ARN-vecteur et pour assurer l'expression spécifique des cellules de protéines ou de peptides, codés par des séquences nucléotidiques d'ADN hétérologues; b) une ou plusieurs séquences nucléotidiques d'ADN codant une protéine ou un peptide, caractérisée(s) en ce que les séquences d'ADN pour assurer l'expression spécifique des cellules contiennent une région de promoteur régulable de manière spécifique des cellules provenant d'une séquence nucléotidique d'ADN rétrovirale endogène humaine (HERV).
EP00918779A 1999-03-10 2000-03-09 Vecteurs d'expression retroviraux a base de sequences herv-ltr (=sequences nucleotidiques d'adn a longue repetition terminale) Withdrawn EP1144667A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19910650A DE19910650A1 (de) 1999-03-10 1999-03-10 Auf HERV-LTR-Sequenzen basierende retrovirale Expressionsvektoren
DE19910650 1999-03-10
PCT/EP2000/002064 WO2000053789A2 (fr) 1999-03-10 2000-03-09 Vecteurs d'expression retroviraux a base de sequences herv-ltr (=sequences nucleotidiques d'adn a longue repetition terminale)

Publications (1)

Publication Number Publication Date
EP1144667A2 true EP1144667A2 (fr) 2001-10-17

Family

ID=7900460

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00918779A Withdrawn EP1144667A2 (fr) 1999-03-10 2000-03-09 Vecteurs d'expression retroviraux a base de sequences herv-ltr (=sequences nucleotidiques d'adn a longue repetition terminale)

Country Status (4)

Country Link
EP (1) EP1144667A2 (fr)
JP (1) JP2002537846A (fr)
DE (1) DE19910650A1 (fr)
WO (1) WO2000053789A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT411262B (de) 2001-09-27 2003-11-25 Wolff Klaus Dr Humanes endogenes retrovirus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE03492B1 (et) * 1994-09-02 2001-08-15 GSF-Forschungszentrum f�r Umwelt und Gesundheit GmbH Mitte-autoinaktiveeruvad ekspressiooni suunavad retroviiruslikud vektorid
DE69627644T2 (de) * 1995-03-09 2004-02-19 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie
EP0817859B1 (fr) * 1995-03-09 2002-01-16 Austrian Nordic Biotherapeutics AG Vecteurs d'adn de recombinaison pour la therapie genique
US6395549B1 (en) * 1998-10-22 2002-05-28 Medical College Of Georgia Research Institute, Inc. Long terminal repeat, enhancer, and insulator sequences for use in recombinant vectors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0053789A2 *

Also Published As

Publication number Publication date
WO2000053789A3 (fr) 2001-04-05
WO2000053789A2 (fr) 2000-09-14
DE19910650A1 (de) 2000-09-21
JP2002537846A (ja) 2002-11-12

Similar Documents

Publication Publication Date Title
DE69636581T2 (de) Retrovirale Vektoren
DE69838758T2 (de) Verfahren und mittel zur herstellung von sicheren, rekombinanten lentivirusvektoren mit hohem titer
JP6001702B2 (ja) ポリプリントラクト改変レトロウイルスベクター
Zhang et al. Lentiviral vectors for sustained transgene expression in human bone marrow–derived stromal cells
DE69936577T2 (de) Lentivirale Verpackungszellen
DE19909769A1 (de) Von SIVagm abgeleitete lentivirale Vektoren, Verfahren zu ihrer Herstellung und ihre Verwendung zur Genübertragung in Säugerzellen
DE60023600T2 (de) Replizierende retrovirale Konstrukte, ihre Herstellung und Verwendungen für den Gentransfer
JP2002510199A (ja) レンチウイルスをベースにした遺伝子転移ベクター
WO2000023606A1 (fr) Longue terminaison repetee, activateur, et sequences isolantes utilises dans des vecteurs recombinants
Dornburg et al. Retroviral vector system for the study of cDNA gene formation
Mager Polyadenylation function and sequence variability of the long terminal repeats of the human endogenous retrovirus-like family RTVL-H
EP1774008A2 (fr) Expression génique inductible
DE69636546T2 (de) Natürliche oder synthetische retroelement-sequenzen, die die insertion von nukleotiden in eukaryotische zellen erlauben
DE68927089T2 (de) Retroviraler vektor
EP0975783B1 (fr) Vecteurs retroviraux, leur procede de production et leur utilisation pour le transfert genique dans des cellules positives cd-4
JP3908274B2 (ja) 遺伝子治療用の抗菌ペプチドをコードする治療用遺伝子を有するベクター
EP1144667A2 (fr) Vecteurs d'expression retroviraux a base de sequences herv-ltr (=sequences nucleotidiques d'adn a longue repetition terminale)
EP0955374B1 (fr) Vecteurs retroviraux pour le transfer de gènes
DE19530412A1 (de) Selbst deletierende retrovirale Vektoren für die Gentherapie
DE60033517T2 (de) Invivo selektionsverfahren zur bestimmung von inhibierenden rna molekülen
US20040248083A1 (en) Vectors for gene therapy
DE69829174T2 (de) Exprimierung eines modifiziertem "foamy virus envelope protein" (hüllenprotein)
EP1195439A2 (fr) Vecteur retroviral contenant des sequences d'insertion heterologues entre le site d'hybridation dû primer retroviral et le site d'epissage doneur retroviral
Kubota et al. Cell-type-specific trans-activation of herpes simplex virus thymidine kinase promoter by the human T-cell leukemia virus type I Tax protein
DE19808438A1 (de) Retrovirale Vektoren, Verfahren zu ihrer Herstellung und ihre Verwendung zur Genübertragung in CD4-positive Zellen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010807

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

XX Miscellaneous (additional remarks)

Free format text: DERZEIT SIND DIE WIPO-PUBLIKATIONSDATEN A3 NICHT VERFUEGBAR.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GSF-FORSCHUNGSZENTRUM FUER UMWELT UND GESUNDHEIT G

17Q First examination report despatched

Effective date: 20040730

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051001